Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.27 MXN
−62.86 M MXN
0.00 MXN
52.56 M
About ORYZON GENOMICS, S.A
Sector
Industry
CEO
Carlos Manuel Buesa Arjol
Website
Headquarters
Barcelona
Founded
2000
ISIN
ES0167733015
FIGI
BBG00ZCWWLN1
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ORYZON GENOMICS, S.A stocks are traded under the ticker ORY/N.
We've gathered analysts' opinions on ORYZON GENOMICS, S.A future price: according to them, ORY/N price has a max estimate of 259.73 MXN and a min estimate of 49.78 MXN. Watch ORY/N chart and read a more detailed ORYZON GENOMICS, S.A stock forecast: see what analysts think of ORYZON GENOMICS, S.A and suggest that you do with its stocks.
Yes, you can track ORYZON GENOMICS, S.A financials in yearly and quarterly reports right on TradingView.
ORYZON GENOMICS, S.A is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
ORY/N earnings for the last quarter are −0.44 MXN per share, whereas the estimation was −0.40 MXN resulting in a −9.44% surprise. The estimated earnings for the next quarter are −0.53 MXN per share. See more details about ORYZON GENOMICS, S.A earnings.
ORYZON GENOMICS, S.A revenue for the last quarter amounts to 16.45 M MXN, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ORY/N net income for the last quarter is 2.08 M MXN, while the quarter before that showed −20.49 M MXN of net income which accounts for 110.13% change. Track more ORYZON GENOMICS, S.A financial stats to get the full picture.
No, ORY/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ORY/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORYZON GENOMICS, S.A stock right from TradingView charts — choose your broker and connect to your account.